Haleon PLC Sponsored ADR $HLN Shares Acquired by Provenance Wealth Advisors LLC

Provenance Wealth Advisors LLC grew its position in Haleon PLC Sponsored ADR (NYSE:HLN) by 26,536.3% in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 79,909 shares of the company’s stock after buying an additional 79,609 shares during the quarter. Provenance Wealth Advisors LLC’s holdings in Haleon were worth $719,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Root Financial Partners LLC purchased a new position in shares of Haleon during the third quarter valued at $25,000. Western Wealth Management LLC purchased a new stake in Haleon in the first quarter worth about $29,000. Annis Gardner Whiting Capital Advisors LLC lifted its stake in Haleon by 402.0% in the first quarter. Annis Gardner Whiting Capital Advisors LLC now owns 3,002 shares of the company’s stock worth $30,000 after acquiring an additional 2,404 shares during the period. Parkside Financial Bank & Trust grew its holdings in Haleon by 20.4% during the 2nd quarter. Parkside Financial Bank & Trust now owns 6,233 shares of the company’s stock worth $58,000 after acquiring an additional 1,055 shares in the last quarter. Finally, Fiduciary Financial Group LLC bought a new position in Haleon during the 2nd quarter worth about $97,000. Institutional investors own 6.67% of the company’s stock.

Haleon Price Performance

NYSE HLN opened at $9.24 on Thursday. The firm’s fifty day simple moving average is $9.47 and its two-hundred day simple moving average is $9.76. The company has a current ratio of 0.69, a quick ratio of 0.52 and a debt-to-equity ratio of 0.38. Haleon PLC Sponsored ADR has a 12-month low of $8.38 and a 12-month high of $11.28. The firm has a market capitalization of $40.69 billion, a P/E ratio of 23.69, a P/E/G ratio of 2.07 and a beta of 0.15.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HLN shares. Berenberg Bank restated a “buy” rating on shares of Haleon in a report on Wednesday, August 5th. Deutsche Bank Aktiengesellschaft raised shares of Haleon from a “sell” rating to a “hold” rating in a research report on Friday, October 30th. Zacks Research downgraded shares of Haleon from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 22nd. Royal Bank Of Canada reissued a “sector perform” rating on shares of Haleon in a report on Tuesday, August 11th. Finally, Jefferies Financial Group downgraded shares of Haleon from a “buy” rating to a “hold” rating in a research note on Wednesday. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating, five have given a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $4.90.

About Haleon

Haleon plc (NYSE: HLN) is a global consumer health company that develops, manufactures and markets over-the-counter medicines, oral health products, vitamins and supplements. Its portfolio is organized around categories including pain relief, respiratory health, digestive health, therapeutic oral care, everyday oral care, vitamins and minerals, and skin health.

Haleon’s well-known brands include Sensodyne, Polident, parodontax, Centrum, Advil, Voltaren, Panadol, Otrivin and Theraflu. The company’s products are sold through pharmacies, supermarkets, retailers and e-commerce channels, serving consumers in markets around the world.

Haleon was established as an independent consumer health business following its demerger from GSK in July 2022.